NCT04521231 2026-03-06
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT07134088 2026-01-29
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Recruiting
NCT03340766 2024-10-17
HARBOUR
Amgen
Phase 1 Completed
NCT02000427 2024-05-28
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2 Completed
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT03476239 2023-02-08
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT01471782 2017-02-08
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
Phase 1/2 Completed
NCT00274742 2015-01-16
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Amgen Research (Munich) GmbH
Phase 1 Completed